01247nas a2200361 4500000000100000008004100001260001300042653001500055653001000070653000900080653001200089653002600101653003000127653001100157653001100168653002300179653001200202653000900214653001600223653001000239100001300249700001500262700001200277700001900289700001500308245010900323856005800432300001000490490000700500050001600507520034800523022001400871 2007 d c2007 Jul10aAdolescent10aAdult10aAged10aDapsone10aDrug Hypersensitivity10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aNepal1 aPandey B1 aShrestha K1 aLewis J1 aHawksworth R A1 aWalker S L00aMortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. uhttp://tdo.sagepub.com/content/37/3/162.full.pdf+html a162-30 v37 aPANDEY 20073 a
Dapsone is a component of multi-drug therapy (MDT) for the treatment of all types of leprosy. It is known that dapsone hypersensitivity syndrome (DHS) complicates the treatment in a proportion of patients. We performed a retrospective study of patients commenced on MDT between 1990 and 2006; 2% developed DHS and 0.25% died due to DHS.
a0049-4755